Trends in the Use of Evidence-based Therapies Early in the Course of Acute Myocardial Infarction and its Influence on Short Term Patient Outcomes by Al-Jarallah, Mohammad et al.
  The Open Cardiovascular Medicine Journal, 2011, 5, 171-178 171 
 
  1874-1924/11  2011 Bentham Open 
Open Access 
Trends in the Use of Evidence-based Therapies Early in the Course of Acute 
Myocardial Infarction and its Influence on Short Term Patient Outcomes  
Mohammad Al-Jarallah
1,*, Mouaz H. Al-Mallah
2, Mohammad Zubaid
3, Alawi A. Alsheikh-Ali
4, 
Wafa Rashed
5, Mustafa Ridha
6, Fahad Alenizi
7, Bassam Bulbanat
1, Mousa Akbar
8,  
Rashed Al-Hamdan
9 and Shahid Zubair
10 
1Division of Cardiology, Al-Amiri Hospital, Kuwait 
2King Abdul-Aziz Cardiac Center, Riyadh, KSA 
3Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait 
4Institute of Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates and Tufts Clinical and 
Translational Science Institute, Tufts University School of Medicine, Boston, MA, USA 
5Division of Cardiology, Mubarak Alkabeer Hospital, Kuwait 
6Division of Cardiology, Aladan Hospital, Kuwait 
7Division of Cardiology, Alfarwaniya Hospital, Kuwait 
8Division of Cardiology, Alsabah Hospital, Kuwait 
9Division of Cardiology, Aljahra Hospital, Kuwait 
10Department of Medicine, Kuwait Oil Company Hospital, Kuwait 
Abstract: Aim: To evaluate changes in management practices and its influence on short term hospital outcomes in pa-
tients with acute myocardial infarction (AMI) admitted during two different time periods, 2007 and 2004. 
Methods and Results: We studied AMI patients from two acute coronary syndrome registries carried out in Kuwait in 
2007 and 2004. We included 1872 and 1197 patients from the 2007 and 2004 registries, respectively. When compared 
with 2004, patients from the 2007 registry had similar baseline clinical characteristics. In 2007 compared to 2004, during 
the in-hospital period, patients with AMI received significantly more statins (94% vs. 73%%, p<0.0001), Angiotensin 
converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) (70% vs. 47%, p<0.001), and Clopidogrel 
(38% vs. 4%, p<0.001), while beta-blockers use dropped in 2007 compared to 2004 (63% vs. 68%, p=0.0066). The rates 
of in-hospital mortality and recurrent ischemia were significantly lower in the 2007 cohort compared with the 2004 cohort 
(for mortality 2.2% vs. 3.9%, P=0.0008, for recurrent ischemia 13.7% vs. 20.4%, P=0<0.0001).Higher utilization of an-
giotensin converting enzyme inhibitors, angiotensin receptor blockers and statins were the main contributors to the im-
proved in-hospital mortality and morbidity.  
In Conclusion: In the acute management of AMI, there was a significant increase in the use of statins, ACE inhibitors and 
Clopidogrel in 2007 compared to 2004. This was associated with a significant decrease in the in-hospital mortality and re-
current ischemia. Adherence to guidelines recommended therapies improved in-hospital outcomes. 
Keywords: Acute Coronary Syndrome, Outcomes, Evidence based therapies. 
INTRODUCTION 
  Guidelines for the management of patients with acute 
coronary syndromes (ACS) recommend interventional and 
pharmacologic strategies that are proven to improve patient 
outcomes [1-3]. However, studies have documented substan-
tial gaps between guideline recommendations and clinical   
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practice [4, 5]. Large multinational registries that reflect   
unselected, non-biased patient management and outcomes 
have shown that adoption of guidelines into routine practice 
is suboptimal and suffers from significant geographical   
and temporal variations [6]. The suboptimal use of guide-
line-recommended therapies include underutilization of 
reperfusion in ST-segment elevation myocardial infarction 
(STEMI), [4] and the suboptimal prescription of statins, 
Clopidogrel and angiotensin converting enzyme (ACE)   
inhibitors [4, 6, 7]. 172    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Al-Jarallah et al. 
  In Kuwait, several registries were carried out to study 
unselected cases of ACS [8-11]. Some of these registries 
have demonstrated suboptimal use of certain proven thera-
pies early in the course of ACS, like ACE inhibitors, statins, 
antiplatelets and interventional procedures [8]. However, the 
extent to which this has changed over time and whether such 
changes are associated with improved outcomes is unknown. 
In the present analysis, we describe temporal changes in the 
utilization of evidence-based therapies early in the course   
of acute myocardial infarction (AMI), and the association 
between such changes and short term patient outcomes,   
utilizing prospectively-collected data from two registries of 
ACS with similar study protocols conducted in two different 
time intervals (2004 and 2007). 
METHODS 
  The present study had four specific aims: 1) describe and 
compare the baseline characteristics of patients with AMI in 
two different time-periods (2007 versus 2004), 2) describe 
temporal trends in the utilization of evidence-based therapies 
early in the course of AMI in 2007 compared to 2004, 3) 
evaluate whether there has been significant improvement in 
short term hospital outcomes among patients with AMI in 
2007 compared to 2004, and 4) assess whether the temporal 
trends in short term patient outcomes are attributed to 
changes in the early utilization of evidence-based therapies. 
To address these aims, we used data from two cohorts of 
patients with AMI enrolled in two separate ACS registries; 
patients enrolled from Kuwait during the Gulf Registry of 
Acute Coronary Events (Gulf RACE), carried out in May 
2006 and from January to June 2007, and patients enrolled in 
the single-country Kuwait acute coronary syndrome (KACS) 
registry, carried out from December 2003 to May 2004.   
The methods of each registry have been previously published 
[8, 10]. 
  Ethics approval was obtained for both registries from the 
country’s ethics approval committee. The two had similar 
study protocols and included consecutive patients admitted 
to the 7 general hospitals in Kuwait with the diagnosis   
of ACS. This included unstable angina, non-ST-segment 
elevation myocardial infarction (NSTEMI) and STEMI. 
KACS registry was carried out in Kuwait only, while   
Gulf RACE was a multinational registry carried out in 6   
Gulf countries including Kuwait. Similar Kuwait-based   
hospitals participated in KACS registry and Gulf RACE. 
These hospitals were Mubarak Al-Kabeer, Al-Amiri, Al-
Adan, Al-Farwaniya, Al-Jahra, Al-Sabah and Kuwait Oil 
Company. At each hospital, designated physicians prospec-
tively identified consecutive patients admitted with ACS 
over a period of 6 months. Similar structured data collection 
forms were used for both registries and were completed dur-
ing hospitalization.  
  Diagnosis of the different types of ACS and definitions 
of data variables were based on the American College of 
Cardiology (ACC) clinical data standards [11]. Myocardial 
infarction was defined as typical rise and gradual fall of bio-
chemical markers of myocardial necrosis with at least one of 
the following (1.Ischemic symptoms, 2.Development of 
pathological Q waves on the ECG, 3. ECG changes sugges-
tive of ischemia (ST-segment elevation or depression).   
Cardiac biomarkers were measured locally at each hospital 
laboratory, using its own assays and reference ranges. Short-
fall was defined as the proportion of patients with STEMI 
who did not receive reperfusion therapy despite presenting 
within 12 hours of symptom onset in the absence of contra-
indications to reperfusion therapy.  
  In both registries, patient treatment and management   
was left to the discretion of the treating physician. The   
present study included data from the AMI populations from 
both registries to compare the treatments they received   
and their hospital outcomes. The primary outcome of   
this analysis was all cause in-hospital mortality. Secondary 
outcomes included in-hospital recurrent ischemia, recurrent 
myocardial infarction, heart failure, cardiogenic shock and 
major bleeding. 
STATISTICAL ANALYSIS 
  Baseline demographics, and clinical and presentation 
characteristics were described and compared between the 
two cohorts (2007 versus 2004) using standard descriptive 
and comparative statistics. Categorical variables are pre-
sented as number of cases and percentage and compared 
using the Chi-square test or Fisher’s exact test as appropri-
ate. Continuous variables are presented as mean ± standard 
deviation or median [25
th – 75
th percentiles] for non-normally 
distributed variables, and compared using independent t-test 
or the non-parametric Mann-Whitney test as appropriate.  
  To compare the utilization of evidence-based therapies 
and in-hospital outcomes in the two cohorts while account-
ing for difference in baseline characteristics, we used a pro-
pensity score methodology. A propensity score for being in 
the 2004 cohort was calculated using logistic regression with 
inclusion in the 2004 cohort as the dependent variable and all 
measured baseline clinical characteristics as independent 
variables.  
  To assess the effect of evidence-based therapies on   
in-hospital death we compared the impact of cohort (2007 
versus 2004) in logistic regression models adjusted for the 
strata of the propensity score with or without including 
treatment variables in the model. All tests were two-sided, 
and a P-value 0.05 was considered significant. All analyses 
were performed with SAS version. 
RESULTS 
Baseline Patient Characteristics  
  There were 1,197 AMI patients in the 2004 cohort regis-
try and 1,872 patients in the 2007 cohort. The two cohorts 
were generally similar in their baseline characteristics with 
regard to age, history of diabetes mellitus, and prior coronary 
artery bypass graft surgery. The 2007 cohort included more 
females, and was more likely to have a history of hyperten-
sion, dyslipidemia, coronary artery disease, prior MI or per-
cutaneous coronary revascularization (Table 1). Differences 
in presentation characteristics were also noted, including 
lower utilization of ambulance services in 2007 and a 
smaller proportion of patients with STEMI. Inpatient angi-
ography rates were similarly low in both cohorts, and most 
patients were managed in an acute care setting.  Trends in the Use of Evidence-based Therapies Early in the Course of Acute  The Open Cardiovascular Medicine Journal, 2011, Volume 5    173 
Temporal Trends in the Early Use of Evidence-Based 
Therapies 
  There were significant differences in the early in-hospital 
use of evidence-based therapies in 2007 compared to 2004 
(Table 2, Fig. 1). The rate of aspirin use was equally high in 
both cohorts. Compared to 2004, patients with AMI in 2007 
were significantly more likely to receive Clopidogrel (38% 
vs. 4%, p<0.0001), statins (94% vs. 73%, p<0.0001), ACE 
inhibitors or angiotensin receptor blockers (ARB) (70% vs. 
Table 1.  Clinical Characteristics of Patients Hospitalized with Acute Myocardial Infarction in 2004 and 2007 
  2004 
N=1197 
2007 
N= 1872  
 
P-value  
Age (mean±SD)   55±13 55±13 0.91 
Male gender  980 (82%)  1460 (78%)  0.0090 
Diabetes  547 (46%)  899 (48%)  0.22 
Hypertension  493 (41%)  947 (51%)  <0.0001 
Current smoking  538 (45%)  759 (41%)  0.0016 
Family history  172 (14%)  225 (12%)  0.06 
Hyperlipidemia  318 (27%)  594 (32%)  0.0024 
Prior CAD  318 (27%)  621 (33%)  <0.0001 
Past history of MI  288 (24%)  560 (29.9%)  <0.0001 
Past history of PCI  79 (6.6%)  249 (13.3%)  <0.0001 
Past history of CABG  57 (4.8%)   106 (5.7%)  0.28 
Heart rate   85 ± 23  86 ±24 0.57 
Systolic BP  139 ±31 142  ± 31  0.01 
Systolic BP<90  46 (3.8%)  39 (2.1%)  0.0046 
Serum creatinine  107±83 89±75 <0.0001 
Peak troponin  26 ±42 26  ±57 0.98 
Use of ambulance  127 (11%)  125 (7%)  <0.0001 
In-hospital Angiography  222 (19%)  330 (18%)  0.53 
Discharge Diagnosis 
STEMI 
NSTEMI 
 
673 (56%) 
524 (44%) 
 
724 (39%) 
1148 (61%) 
<0.0001 
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary, coronary artery bypass grafting; BP, blood pressure ECG, electrocardiogram and ICU, inten-
sive care unit. 
 
Table 2.  Rate of Utilization of Pharmacological Therapies in Patients with Acute Myocardial Infarction in 2004 and 2007 
  2004 
N=1197 
2007 
N= 1872 
 
P-value 
Aspirin  1165 (97%)  1836 (98%)  0.17 
Clopidogrel  48 (4%)  702 (38%)  <0.0001 
LMWH  95 (8%)  537 (29%)  <0.0001 
UFH 1061(89%)  1298  (69%)  <0.0001 
Beta-Blocker  815 (68%)  1184 (63%)  0.0066 
ACE-I or ARB  566 (47%)  1312 (70%)  <0.0001 
Statin  869 (73%)  1768 (94%)  <0.0001 
Diuretics  250 (21%)  472 (25%)  0.006 
LMWH, Low molecular weight heparin; UFH, unfractionated heparin; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. 174    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Al-Jarallah et al. 
47%, p<0.0001), and low molecular weight heparin 
(LMWH) (29% vs. 8%, p<0.0001). The use of beta-blockers 
declined from 68% in 2004 to 63% in 2007 (p=0.0066). The 
significant differences in early utilization of evidence-based 
therapies in the two time-periods persisted after adjusting for 
the strata of the propensity score (Fig. 1). 
  Among patients with STEMI (Table 3), thrombolytic 
therapy was the sole mode of reperfusion and most patients 
who were candidates for thrombolytic therapy were similarly 
likely to receive it in both cohorts (short fall 7.8% in 2007 
versus 6.1% in 2004, P=0.28). The median time from first 
diagnostic electrocardiogram (ECG) to administration of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Odds ratios of utilizing evidence-based therapies between 2004 and 2007 with and without adjustment with the propensity score. 
Table 3.  Clinical Variables and Type of Thrombolytic Used in the ST Segment Elevation Myocardial Infarction (STEMI) Popula-
tion in 2004 and 2007 
  2004 
N=673 
2007 
N=724 
 
P value 
Type of Thrombolytic   
tPA 
SK 
Reteplase 
TNK 
 
10 (1.8%) 
14 (2.5%) 
254 (45.9%) 
276 (49.8%) 
 
6 (1.0%) 
1 (0.2%) 
301 (53.2%) 
258 (45.6%) 
 
 
0.0008 
Diagnostic ECG to Thrombolysis time (Median, IQ)  38 (24 – 60)  29 (16 -50)  <0.0001 
Shortfall   36/590 (6.1%)  47/611 (7.8%)  0.28 
Delayed Presentation  72 (10.7%)  105 (14.5%)  0.033 
tPA, tissue plasminogen activator; SK,Strptokinase; TNK, Tenecteplase. Shortfall is defined as the patients presenting with STEMI within 12 hours of symptom onset in the absence 
of contraindication to thrombolytic therapy and did not receive it. Trends in the Use of Evidence-based Therapies Early in the Course of Acute  The Open Cardiovascular Medicine Journal, 2011, Volume 5    175 
thrombolytic therapy shortened significantly in 2007 com-
pared to 2004 (29 minutes vs. 38 minutes, p<0.0001). 
Temporal Trends in Short Term Patient Outcomes 
 Table  4 displays the crude in-hospital outcome rates for 
the two time-periods. In univariate analysis, there was a sig-
nificant decrease in in-hospital mortality (2.2% vs. 3.9%, 
P<0.001) as well as recurrent ischemia (13.7% vs. 20.4%, 
P<0.0001) in 2007 compared to 2004 and a non-significantly 
lower rate of recurrent MI favoring 2007 (2.2% vs. 3.3%, 
P=0.08). There were no significant differences in the rates of 
other in-hospital outcomes including heart failure, cardio-
genic shock, stroke, or major bleeding. 
  Multivariable analysis was performed to determine the 
impact of early pharmacologic interventions on all-cause 
mortality (Fig. 2). The unadjusted odds ratio (OR) showed 
Table 4.  In-Hospital Outcomes of Patients with Acute Myocardial Infarction in 2004 and 2007 
  2004 
N=1197 
2007 
N= 1872 
 
P-value 
Death   47 (3.9%)  42 (2.2%)  0.0008 
Recurrent ischemia   244 (20.4%)  257 (13.7%)  <0.0001 
Recurrent MI  39 (3.3%)  41 (2.2%)  0.08 
Heart Failure  130 (10.9%)  231 (12.3%)  0.23 
Cardiogenic shock  43 (3.6%)  64 (3.4%)  0.84 
Stroke   3 (0.25%)  5 (0.27%)  0.93 
Major bleed  10 (0.8%)  9 (0.4%)  0.24 
Death or MI  81 (6.8%)  81 (4.3%)  0.0037 
Death or MI or ischemia  284 (23.7%)  189 (15.3%)  <0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effects of utilizing evidence-based therapies on 2004 mortality after adjustment for the propensity score. 176    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Al-Jarallah et al. 
an increased mortality in 2004 (1.8 [1.2-2.7]). Adjusting   
for ACE inhibitors or ARB as well as adjusting for statin 
therapy neutralized the difference between the two cohorts. 
Adjusting for different combination of medications is also 
shown in Fig. (2). The decreased utilization of beta blockers, 
on the other hand, had offset some of the beneficial effects of 
statins and ACE inhibitors. 
  Similar modeling was repeated after adjusting for the 
propensity score (Fig. 3). Before adjustment, the model sug-
gested that patients admitted in 2004 had 80% higher likeli-
hood of in-hospital mortality compared to 2007 (OR 1.8). 
This continued to be significant after adjusting for the   
propensity score. A model adjusting for all therapies and   
the propensity score showed that there were no significant 
differences in mortality between the two cohorts. This was 
especially true when adjustment was only done for ACEI/ 
ARBs and statins. 
DISCUSSION 
  We examined our practice to find out the extent to which 
cardiologists in Kuwait have improved their early manage-
ment of AMI and the influence of such change on short term 
patients outcomes. We have demonstrated two important 
findings. First, the early management of AMI in this part of 
the Middle East has changed to the better. Second, this 
change has resulted in significant improvement in short term 
outcomes of mortality and recurrent ischemia. This im-
provement in practice involved shorter diagnostic ECG to 
needle time (in patients with STEMI) and higher rates of 
utilization of ACE inhibitors and statins, as well as better use 
of other proven therapies like Clopidogrel and low molecular 
weight heparin. 
  The last two decades have witnessed advances in the 
management of AMI at the interventional and pharmacother-
apy levels [12-26]. The influence of these changes on out-
come is well documented in several large trials [26-39]. The 
additive effects of these interventions can lead to an 80% 
reduction in adverse events [40]. These advances have re-
sulted in the formation of guidelines that address the proper 
treatment and management of patients with AMI [2, 3]. Data 
show that physicians do not embrace guidelines immediately 
and, as a result, a gap exists between recommendations and 
implementation [4-6].  
  We did observe a significant improvement of in-hospital 
outcomes including lower in-hospital mortality and recurrent 
ischemia. This better outcome was despite the fact that the 
characteristics and risk status of AMI patients at presentation 
suggested that the 2007 group was a higher risk population 
due to the inclusion of more patients with hypertension, pre-
vious percutaneous coronary interventions and myocardial 
infarction. In an attempt to understand the reasons behind 
this improvement in short term outcomes, we carried out 
further analysis taking into account the different therapies 
that were provided. Our analysis demonstrated increased 
utilization of multiple drugs that were shown to reduce   
adverse cardiovascular outcomes in patients with ACS.   
Despite this improvement in practice, the rates of utilization 
of some of these drugs are still below the current standard 
when compared to other larger multinational registries [5]. 
For example, the rate of utilization of beta-blockers and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Effects of utilizing evidence-based therapies on 2004 mortality after adjustment for the propensity score. Trends in the Use of Evidence-based Therapies Early in the Course of Acute  The Open Cardiovascular Medicine Journal, 2011, Volume 5    177 
Clopidogrel is low in our registry compared to the Grace 
registry. 
  Our understanding of the pathophysiology of atheroscle-
rosis and the mechanisms of myocardial infarction has 
evolved over the last few decades. Multiple randomized con-
trol trials have suggested that some drugs have a significant 
role in lowering early cardiovascular mortality when used in 
the acute phase [26, 32, 37, 38]. In particular, in the Fourth 
International Study of Infarct Survival (ISIS-4) trial, the ef-
fect of ACE inhibitor on mortality was demonstrated as early 
the first 24 hours of the treatment initiation and persisted up 
to one year [37]. In pravastatin or atorvastatin evaluation and 
infarction therapy (PROVE-IT trial), high dose statin re-
duced mortality with a benefit that was apparent within the 
first 30 days of treatment initiation [38]. Our findings that 
statins and ACE inhibitors were the major contributors to the 
decreased in-hospital mortality in 2007 compared to 2004 is 
in keeping with the published literature. It is also conceiv-
able that more frequent use of statins and ACE inhibitors are 
markers of other processes of care that were not measured 
but had a favorable effect on short term outcomes. 
STRENGTHS AND LIMITATIONS 
  The data we presented were derived from all consecutive 
AMI patients admitted to all hospitals in Kuwait during the 
two different study periods. While selection bias cannot be 
excluded, we believe our sample represents the practice of 
AMI management during those times. To our knowledge, 
this study is the first from the Arab world and Gulf region 
that looks at changes in the early management of AMI pa-
tients and its influence on short term outcomes. Our findings 
are limited by the fact that we were not able to adjust for 
other important variables such as ejection fraction and angi-
ographic severity of coronary artery disease. Also, the obser-
vational nature of the study precludes us from inferring 
cause-and-effect associations between treatment patterns and 
in-hospital outcomes but it is highly plausible that the 
changes in clinical outcomes are the direct consequence of 
changes in practice. 
CONCLUSIONS AND IMPLICATIONS 
  Our analysis demonstrated a significant favorable change 
towards the adoption of guidelines-recommended therapies 
in patients admitted with AMI. This change was associated 
with a lower in-hospital mortality and recurrent ischemia. 
These data provide a strong argument in favor of continued 
educational efforts to increase the adoption of guidelines in 
the management of patients with AMI.  
  A significant effort needs to be made to educate provid-
ers (both physicians and nurses), identify barriers, and as-
semble a multidisciplinary team that would be able to impact 
the process of care in the coronary care units. The use of 
standardized myocardial infarction admission and discharge 
orders and care pathways may help to increase the imple-
mentation of guidelines-recommended therapies in the care 
of AMI patients. 
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